JP7799262B2 - グレリン受容体作用剤としてのトリアゾール化合物の用途 - Google Patents

グレリン受容体作用剤としてのトリアゾール化合物の用途

Info

Publication number
JP7799262B2
JP7799262B2 JP2023518498A JP2023518498A JP7799262B2 JP 7799262 B2 JP7799262 B2 JP 7799262B2 JP 2023518498 A JP2023518498 A JP 2023518498A JP 2023518498 A JP2023518498 A JP 2023518498A JP 7799262 B2 JP7799262 B2 JP 7799262B2
Authority
JP
Japan
Prior art keywords
ghrelin receptor
cachexia
induced
carbon atoms
ghrelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023518498A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542964A (ja
JP2023542964A5 (https=
Inventor
ぺ，ジェソン
ジン，ヒギョン
ヒー パク，ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of KNU
Original Assignee
Industry Academic Cooperation Foundation of KNU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of KNU filed Critical Industry Academic Cooperation Foundation of KNU
Publication of JP2023542964A publication Critical patent/JP2023542964A/ja
Publication of JP2023542964A5 publication Critical patent/JP2023542964A5/ja
Application granted granted Critical
Publication of JP7799262B2 publication Critical patent/JP7799262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/30—Other Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2023518498A 2020-09-22 2021-09-17 グレリン受容体作用剤としてのトリアゾール化合物の用途 Active JP7799262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200122540 2020-09-22
KR10-2020-0122540 2020-09-22
PCT/KR2021/012823 WO2022065831A1 (ko) 2020-09-22 2021-09-17 그렐린 수용체 작용제로서의 트리아졸 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2023542964A JP2023542964A (ja) 2023-10-12
JP2023542964A5 JP2023542964A5 (https=) 2024-08-15
JP7799262B2 true JP7799262B2 (ja) 2026-01-15

Family

ID=80845629

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518498A Active JP7799262B2 (ja) 2020-09-22 2021-09-17 グレリン受容体作用剤としてのトリアゾール化合物の用途

Country Status (6)

Country Link
US (1) US12570617B2 (https=)
EP (1) EP4218757A4 (https=)
JP (1) JP7799262B2 (https=)
KR (1) KR102752714B1 (https=)
CN (2) CN116669575B (https=)
WO (1) WO2022065831A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022448086B2 (en) * 2022-03-23 2024-02-01 Nextgen Bioscience Co., Ltd. Pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for s1pr1 and s1pr4

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018062638A1 (en) 2016-09-30 2018-04-05 Kyungpook National University Industry-Academic Cooperation Foundation Composition for treating a neurodegenerative disease and depression comprising derivatives of 2-amino-2-(1-dodecyl-1h-l,2,3-triazol-4-yl)propane- 1,3-diol as an active ingredient
WO2019212196A1 (ko) 2018-04-30 2019-11-07 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal
US10975070B2 (en) * 2010-02-26 2021-04-13 Raqualia Pharma Inc. Ghrelin receptor agonist for treatment of cachexia
EP2431035A1 (en) * 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
KR20150020602A (ko) * 2012-05-25 2015-02-26 라퀄리아 파마 인코포레이티드 무산증 치료를 위한 그렐린 수용체 효능물질
ES2864079T3 (es) * 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en) * 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
KR101830244B1 (ko) * 2016-01-20 2018-02-21 서울대학교 산학협력단 신규한 헤테로방향족 고리 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 s1p 수용체 관련 질환의 예방 또는 치료용 약학적 조성물
KR102292989B1 (ko) 2017-03-29 2021-08-26 재단법인 아산사회복지재단 S1pr4를 타겟으로 하는 비알코올성 지방간염 예방 또는 치료용 조성물
KR102609693B1 (ko) 2019-04-18 2023-12-05 현대모비스 주식회사 차량의 전원 백업 장치

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018062638A1 (en) 2016-09-30 2018-04-05 Kyungpook National University Industry-Academic Cooperation Foundation Composition for treating a neurodegenerative disease and depression comprising derivatives of 2-amino-2-(1-dodecyl-1h-l,2,3-triazol-4-yl)propane- 1,3-diol as an active ingredient
WO2019212196A1 (ko) 2018-04-30 2019-11-07 경북대학교 산학협력단 신규한 asm 활성 직접 억제 화합물 2-아미노-2-(1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체 및 이의 용도

Also Published As

Publication number Publication date
CN116669575A (zh) 2023-08-29
EP4218757A1 (en) 2023-08-02
CN116669575B (zh) 2025-04-04
US12570617B2 (en) 2026-03-10
US20230339869A1 (en) 2023-10-26
WO2022065831A1 (ko) 2022-03-31
KR102752714B1 (ko) 2025-01-10
JP2023542964A (ja) 2023-10-12
CN120081796A (zh) 2025-06-03
EP4218757A4 (en) 2024-11-13
KR20220039625A (ko) 2022-03-29

Similar Documents

Publication Publication Date Title
EA018894B1 (ru) N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция
EA007921B1 (ru) Лечение атрофии мышц с помощью селективных модуляторов андрогенового рецептора
JP2022514722A (ja) 新規ａｓｍ活性直接抑制化合物２－アミノ－２－（１，２，３－トリアゾール－４－イル）プロパン－１，３－ジオール誘導体及びその用途
JP7799262B2 (ja) グレリン受容体作用剤としてのトリアゾール化合物の用途
EP1506777A1 (en) Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient
EP4327825A1 (en) Therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance
US20190231898A1 (en) Pharmaceutical composition containing hyaluronic acid nanoparticles for preventing or treating inflammatory disease and metabolic disease
EP2263666A1 (en) Agent and food for prevention/amelioration of functional gastrointestinal disorders
WO2013073698A1 (ja) Cxcr4活性阻害ペプチド及びその用途
JP2002193797A (ja) インスリン抵抗性改善用組成物
CN1681514A (zh) 一种治疗糖尿病,包括与糖尿病有关的疾病和糖尿病并发症的方法
EA034427B1 (ru) Производные индола
TW201026319A (en) Peptide having anti-diabetic activity and use thereof
KR100886466B1 (ko) 신규한 스티그마스테롤 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법, 및 이를 포함하는 비만억제 또는 고지혈증 예방 및 치료용 조성물
JP5849465B2 (ja) アディポネクチン産生促進剤
JP6028596B2 (ja) 循環器系疾患の予防・治療効果に対するフラボノール類・シナピン酸反応生成物
KR20080069233A (ko) 위장관 기능 촉진제
KR20220151044A (ko) 바이구아나이드 약물을 이용한 대사 이상 동반된 mcp1 과도 활성 골관절염 질환 치료 주사 조성물
KR102114197B1 (ko) 신규한 벤질리덴아세톤 유도체 및 이의 용도
JP6070264B2 (ja) 循環器系疾患の予防・治療効果に対するフラボノール類・シナピン酸反応生成物
JP6742853B2 (ja) 持続性ケルセチン配糖体製剤
KR20210125809A (ko) 살비아놀산 b를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
JP4790803B2 (ja) 化合物、α１アドレナリン受容体拮抗剤、及び組成物
JP2012184176A (ja) ＰＰＡＲγ活性化剤
JP2025523618A (ja) 乳酸カルシウムを有効成分として含有するがん悪液質の改善又は治療用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7799262

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150